NETO1 and ovarian carcinoma: To sum up, our study revealed that NETO1 might enhance migration and invasive potential of EOC, modulate the expression of cytoskeletal genes and promote tumour development, progression and metastasis. Therefore, NETO1 may serve as a potential biomarker to identify a subgroup of patients with a more aggressive phenotype of ovarian cancer.